Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Node-negative Breast Cancer”

2,874 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 2,874 results

Large-scale testing (Phase 3)Active Not RecruitingNCT04305496
What this trial is testing

Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

Who this might be right for
Locally Advanced (Inoperable) or Metastatic Breast Cancer
AstraZeneca 818
Testing effectiveness (Phase 2)Looking for participantsNCT05190094
What this trial is testing

Prediction of Treatment Efficacy of the Combination of Palbociclib/(Letrozole or Anastrozole) in First Line Metastatic Women With Luminal, HER2 Negative Advanced Breast Cancer, Using Infrared Laser Spectroscopy Analysis on Liquid Biopsies.

Who this might be right for
Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer
International Cancer Research Group, United Arab Emirates 80
Large-scale testing (Phase 3)Looking for participantsNCT07207070
What this trial is testing

A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.

Who this might be right for
Breast Cancer
Risen (Suzhou) Pharma Tech Co., Ltd. 312
Not applicableEnded earlyNCT05742269
What this trial is testing

Molecular PD-L1 PET/CT Imaging With 89Zr-atezolizumab in Metastatic Triple Negative Breast Cancer

Who this might be right for
Metastatic Triple-Negative Breast Carcinoma
Karolinska University Hospital 3
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07658183
What this trial is testing

A Clinical Trial Comparing the Efficacy and Safety of Different Doses of BL0175 Injection in Treating Postmenopausal Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer (Locally Advanced or Metastatic)
Shanghai Best-Link Bioscience, LLC 120
Not applicableActive Not RecruitingNCT07092254
What this trial is testing

Patterns of Care and Outcomes in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
Daiichi Sankyo 760
Early research (Phase 1)Looking for participantsNCT04872166
What this trial is testing

BTX-A51 in People With Advanced Solid Tumor and Breast Cancer

Who this might be right for
Advanced Solid TumorMetastatic Breast Cancer
Edgewood Oncology Inc. 112
Not applicableEnded earlyNCT04370522
What this trial is testing

Characterization of Innate Immune System in Patients With Luminal Advanced Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Spanish Breast Cancer Research Group 32
Testing effectiveness (Phase 2)Active Not RecruitingNCT05383196
What this trial is testing

Onvansertib + Paclitaxel In TNBC

Who this might be right for
Breast CancerInvasive Breast CancerUnresectable Breast Carcinoma+7 more
Antonio Giordano, MD 50
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07005583
What this trial is testing

Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast Cancer

Who this might be right for
Triple-Negative Breast Cancer (TNBC)
Tianjin Medical University Cancer Institute and Hospital 46
Testing effectiveness (Phase 2)Looking for participantsNCT06492005
What this trial is testing

A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer

Who this might be right for
Triple-Negative Breast Cancer
Mabwell (Shanghai) Bioscience Co., Ltd. 160
Testing effectiveness (Phase 2)Ended earlyNCT04720729
What this trial is testing

Chemotherapy Monitoring by ctDNA in HER2- Metastatic Breast Cancer

Who this might be right for
HER2-negative Metastatic Breast Cancer
Institut Curie 160
Early research (Phase 1)Ended earlyNCT03292172
What this trial is testing

Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer

Who this might be right for
Advanced Ovarian CancerTriple Negative Breast Cancer
Hoffmann-La Roche 36
Not applicableStudy completedNCT03523195
What this trial is testing

Exercise Intervention After Cancer Treatment for Improving Health in Stage II-III Breast Cancer Survivors

Who this might be right for
Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8+16 more
Fred Hutchinson Cancer Center 20
Not applicableLooking for participantsNCT05378204
What this trial is testing

Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.

Who this might be right for
Breast Cancer
Institut Claudius Regaud 120
Early research (Phase 1)Looking for participantsNCT05005403
What this trial is testing

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Who this might be right for
Non-Small Cell Lung CancerHead and Neck Squamous Cell CarcinomaMicro Satellite Stable Colorectal Cancer+4 more
AbbVie
Large-scale testing (Phase 3)UnknownNCT01622361
What this trial is testing

Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer

Who this might be right for
Breast Cancer
Asan Medical Center 290
Not applicableWithdrawnNCT01936961
What this trial is testing

Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors

Who this might be right for
Metastatic Non-Small Cell Lung CancerMetastatic Colon CancerMetastatic Triple Negative Breast Cancer
Western Regional Medical Center
Testing effectiveness (Phase 2)Study completedNCT05383170
What this trial is testing

Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers

Who this might be right for
Advanced Head and Neck Squamous Cell CarcinomaAdvanced Breast CancerAdvanced Melanoma
Cytovation AS 6
Testing effectiveness (Phase 2)Study completedNCT02491983
What this trial is testing

Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast Cancer

Who this might be right for
Metastatic Breast Cancer
MedSIR 486
Next Page
694